Refine by
Oncogene Suppliers & Manufacturers
25 companies found
based inBeijing, CHINA
In 2006, TransGen Biotech Co., Ltd was founded by three scientists with a mission to produce innovative and cost-effective products for life science research. Now TransGen is a leading manufacturer of more than 200 molecular and cellular biology ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
based inSeattle, WASHINGTON (USA)
SEngine Precision Medicine empowers patients and oncologists with more informed treatment options. SEngine's high-throughput technology simultaneously tests more than 200 cancer drugs against a patient's unique tumor organoid outside the body. The ...
Guiding drug discovery with proprietary high throughput 3D patient cell technology and genomics will drastically increase the success of novel drug candidates and directly result in faster development at reduced costs. SEngine Precision ...
based inKitchener, ONTARIO (CANADA)
Biomatik primarily focused on Biochemicals, Enzymes, Gene Synthesis, and Peptide Synthesis services in the early years, but has since rapidly expanded its offerings to include ELISA Kits, Protein Production, Antibody Production, and Antibody ...
based inYongin-si, SOUTH KOREA
Txinno Bioscience is developing anti-cancer treatments focused on two intertwined aspects of physiology of tumor tissue. Tcino Bioscience Co., Ltd. has secured and built core platform technologies such as small molecule innovative anticancer drug ...
RAS GTPase family has 3 members encoding KRAS, HRAS and NRAS proteins which are involved in controlling normal growth signal. RAS GTPases are also well-known oncogenes that drive tumorigenesis when mutation is ...
based inChicago, ILLINOIS (USA)
Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we ...
Tempus xE (version 2) is a whole exome next-generation sequencing assay that analyzes the entire coding region (exome) of the patient’s genome, combined with whole transcriptome RNA sequencing. Clinical sequencing is performed to 500x depth of ...
based inMorrisville, NORTH CAROLINA (USA)
Our mission is to provide comprehensive personalized molecular solutions to inform cancer care. NantOmics, a member of the NantWorks ecosystem of companies, is a leader in molecular diagnostic testing and the first company to employ an integrated ...
based inSeoul, SOUTH KOREA
NGS industries are rapidly evolving and our customers are in greater need of technical support in various research fields and markets. Just like a chameleon utilizing its colored pigments and crystals to adapt to its surroundings, we proactively ...
Celemics’ Oncorisk Panel is specifically designed to analyze hereditary cancer associated genes. The OncoRisk Panel targets 31 well-known oncogenes, leading to a reduction of totalsequencing cost compared to whole genome ...
based inVerona, ITALY
At Sibylla Biotech, we face the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs. Born out of a scientific challenge, the PPI-FIT protocol (Pharmacological Protein Inactivation by Folding ...
based inVienna, AUSTRIA
A spin-off from the University of Veterinary Medicine Vienna, ViruSure was founded in 2005 by Dr. Andy Bailey to offer a range of biosafety testing services to biopharmaceutical product manufacturers. Since 2008, ViruSure’s in vitro and molecular ...
Gene therapy has brought hope to many diseases with unmet clinical need. The potential to permanently cure the patient through replacement of a defective gene with a healthy gene underscores the surge of interest in this exciting biopharma ...
based inUdine, ITALY
Ulisse BioMed is an Italian healthcare biotech company with corporate offices in Udine, Italy and with R&D and Manufacturing labs in Trieste, Italy. Ulisse BioMed is creating novel, innovative and transformative diagnostic platforms and products. ...
Ulisse BioMed proposes a specific offer for the detection and genotyping of Human Papillomavirus (HPV) to physicians and professionals in the gynecological ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
INH154 is a highly potent inhibitor for Nek2 and Hec1 binding (INH), with IC50s of 200 nM and 120 nM for INH in Hela and MB468 ...
based inxiamen, CHINA
XIAMEN SPACEGEN Co., Ltd. is a high-tech molecular diagnostic biology enterprise integrating R&D, production, sales and service. The company leads technological innovation guided by clinical needs ，providing high-quality and accessible molecular ...
Detection Gene:NTRK1, NTRK2 and NTRK3 gene fusion detection. Detection Significance:Guiding the selection of NTRK ...
based inMunich, GERMANY
Isarna Therapeutics was built on profound knowledge in antisense oligonucleotide design and therapeutic development of this innovative compound class. Today, Isarna is developing a portfolio of antisense therapies targeting an emerging therapeutic ...
Transforming growth factor beta (TGF-β) plays an important role in key biological processes such as cell proliferation, cell differentiation, immune response and tissue modeling. Because TGF-β is chronically elevated in many diseases, ...
based inNavi Mumbai, INDIA
Yashraj Biotech Limited manufactures a wide range of high pure biomarkers in the form of native and recombinant proteins that are used by the diagnostic industry as controls, calibrators and immunogens. YBL has been the preferred partner of most of ...
Yashraj Biotechnology Ltd.’s (YBL) offers Development of Primary Cell line(s), both from normal and tumor tissues. YBL offers Transformation of cell lines by introduction of external DNA that drives the Transformation process by sustaining ...
based inMumbai, INDIA
Lupin is a global pharmaceutical company offering a wide range of products such as Branded & Generic Formulations, Biotechnology Products, Active Pharmaceutical Ingredients (APIs) and Specialty. Lupin is a significant player in the therapy areas of ...
The NDDD team has developed a pipeline of highly differentiated and innovative new chemical entities in focused therapeutic areas of Oncology, Immunology and Metabolic ...
based inMilford, MASSACHUSETTS (USA)
SeraCare is a leading partner and supplier of diagnostic quality controls, biological materials, and reagents to in vitro diagnostics developers, clinical laboratories, and life science researchers worldwide. Since the early 1980s, we have supported ...
The Seraseq Tumor Mutation DNA Mix v2 (AF7) HC is a multiplexed mixture of actionable biosynthetic DNA targets precisely blended with a single, well-characterized genomic background. This product is produced under rigorous design control and ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Tulmimetostat is a second-generation EZH2 inhibitor that has been designed to achieve comprehensive target coverage through extended on-target residence time. EZH2 acts as an epigenetic writer and normally places one or more methyl groups on a ...
based inOxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
based inCarlsbad, CALIFORNIA (USA)
Qualigen is a biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack diagnostic platform. The FastPack line of FDA-cleared and ...
Our RAS-F portfolio includes lead and back-up small molecules that suppress the interaction of endogenous RAS with c-RAF, upstream of the KRAS, HRAS, and NRAS effector pathways. This potentially enables a differentiated, RAS-targeted strategy for ...